Ivabradine HCL

Global Calcium is one of the leading manufacturers and exporters of Ivabradine HCL CAS no. 148849-67-6, API, (Active Pharmaceutical Ingredient). We support the customers with exhaustive documentation. As a USDMF & EU-GMP certified global company and an established hallmark for pharmaceutical standards, Global Calcium has stood the test of time since its inception in 1979.

As manufacturer of Ivabradine HCL we hereby state the following facts about the drug:

Ivabradine acts as novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.

Ivabradine was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose.

Ivabradine is extremely successful agent to reduce risk of hospital admission for worsening heart failure.

The cardiac effects of ivabradine are specific to the SA node, and the drug has no effect on blood pressure, intracardiac conduction, myocardial contractility, or ventricular repolarization.

Ivabradine blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker if current, which regulates heart rate. There was no effect on ventricular repolarization and no effects on myocardial contractility. Ivabradine can also inhibit the retinal current.

Peak plasma ivabradine concentrations are reached in approximately 1 hour under fasting conditions. The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver. Food delays absorption by approximately 1 hour and increases plasma exposure by 20% to 40%.

Global Calcium is a leading manufacturer of this drug. We manufacture this pharmaceutical drug and make it available to domestic and overseas market